The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators

Journal of Molecular Biology

Volumn 393, Issue 3, 2009, Pages 672-692

  Dimasi, Nazzareno ^a   Gao, Changshou ^a   Fleming, Ryan ^a   Woods, Robert M ^a   Yao, Xiao Tao ^a   Shirinian, Lena ^a   Kiener, Peter A ^a   Wu, Herren ^a  

^a MEDIMMUNE   (United States)

Author keywords

antibody expression; antibody stability; bispecific antibody; concurrent binding; oligospecific antibody

Indexed keywords

ANTIBODY; ANTIGEN; BS1 ANTIBODY; BS2 ANTIBODY; BS3 ANTIBODY; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; PROTEINASE; TS1 ANTIBODY; TS2 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME MECHANISM; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THERMOSTABILITY;

MAMMALIA;

EID: 70349785100     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.08.032     Document Type: Article

References (53)

1. Graul A.I., Prous J.R., Barrionuevo M., Bozzo J., Castaner R., Cruces E., et al. The year's new drugs and biologics-2007. Drug News Perspect 21 (2008) 7-35
2. Nissim A., and Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb. Exp. Pharmacol. 181 (2008) 3-18
3. Liu X.Y., Pop L.M., and Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol. Rev. 222 (2008) 9-27
4. Oldham R.K., and Dillman R.O. Monoclonal antibodies in cancer therapy: 25 years of progress. J. Clin. Oncol. 26 (2008) 1774-1777
5. Lawrence S. Billion dollar babies-biotech drugs as blockbusters. Nat. Biotechnol. 25 (2007) 380-382
6. Frantz S. Drug discovery: playing dirty. Nature 437 (2005) 942-943
7. Petrelli A., and Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15 (2008) 422-432
8. Wu C., Ying H., Grinnell C., Bryant S., Miller R., Clabbers A., et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 11 (2007) 1290-1297
9. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol. 25 (2007) 390-394
10. Marvin J.S., and Zhu Z. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr. Opin. Drug Discov. Dev. 9 (2006) 184-193
11. Tolstrup A.B., Frandsen T.P., and Bregenholt S. Development of recombinant human polyclonal antibodies for the treatment of complex human diseases. Expert. Opin. Biol. Ther. 9 (2006) 905-912
12. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12 (2006) 693-698
13. Leonard J.P., Coleman M., Ketas J., Ashe M., Fiore J.M., Furman R.R., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 23 (2005) 5044-5051
14. Strauss S.J., Morschhauser F., Rech J., Repp R., Solal-Celigny P., Zinzani P., et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 24 (2006) 3880-3886
15. Ye D., Mendelsohn J., and Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18 (1999) 731-738
16. Kawaguchi Y., Kono K., Mimura K., Mitsui F., Sugai H., Akaike H., and Fujii H. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br. J. Cancer 97 (2007) 494-501
17. Friedman L.M., Rinon A., Schechter B., Lyass L., Lavi S., Bacus S.S., et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA 102 (2005) 1915-1920
18. Farid S.S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B 848 (2007) 8-18
19. Birch J.R., and Racher A.J. Antibody production. Adv. Drug Deliv. Rev. 58 (2006) 671-685
20. Scott C.T. The problem with potency. Nat. Biotechnol. 23 (2005) 1037-9103
21. Filpula D. Antibody engineering and modification technologies. Biomol. Eng. 24 (2007) 201-215
22. Kontermann R.E. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol. Sin. 26 (2005) 1-9
23. Jain M., Kamal N., and Batra S.K. Engineering antibodies for clinical applications. Trends Biotechnol. 25 (2007) 307-316
24. Pack P., and Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 31 (1992) 1579-1584
25. Qiu X.Q., Wang H., Cai B., Wang L.L., and Yue S.T. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat. Biotechnol. 8 (2007) 921-929
26. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl Acad. Sci. USA 85 (1988) 5879-5883
27. Holliger P., Prospero T., and Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA 90 (1993) 6444-6448
28. Zhu Z., Zapata G., Shalaby R., Snedecor B., Chen H., and Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 14 (1996) 192-196
29. McCartney J.E., Tai M.S., Hudziak R.M., Adams G.P., Weiner L.M., Jin D., et al. Engineering disulfide-linked single-chain Fv dimers (sFv')2 with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides. Protein Eng. 8 (1995) 301-314
30. Iliades P., Kortt A.A., and Hudson P.J. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409 (1997) 437-441
31. Todorovska A., Roovers R.C., Dolezal O., Kortt A.A., Hoogenboom H.R., and Hudson P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 248 (2001) 47-66
32. Hust M., Jostock T., Menzel C., Voedisch B., Mohr A., Brenneis M., Kirsch M.I., Meier D., and Dübel S. Single chain Fab (scFab) fragment. BMC Biotechnol. 8 (2007) 7-14
33. Stone E., Hirama T., Tanha J., Tong-Sevinc H., Li S., MacKenzie C.R., and Zhang J. The assembly of single domain antibodies into bispecific decavalent molecules. J. Immunol. Methods 318 (2007) 88-94
34. Coloma M.J., and Morrison S.L. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15 (1997) 159-163
35. Shen J., Vil M.D., Jimenez X., Zhang H., Iacolina M., Mangalampalli V., et al. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J. Immunol. Methods 318 (2007) 65-74
36. Guo L., Chowdhury P., Glasscock J.M., and Gai F. Denaturant-induced expansion and compaction of a multi-domain protein: IgG. J. Mol. Biol. 384 (2008) 1029-1036
37. Starr T.E., and Thompson N.L. Local diffusion and concentration of IgG near planar membranes: measurement by total internal reflection with fluorescence correlation spectroscopy. J. Phys. Chem. B 106 (2002) 2365-2371
38. Armstrong J.K., Wenby R.B., Meiselman HJ., and Fisher T.C. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. Biophys. J. 87 (2004) 4259-4270
39. Garber E., and Demarest S.J. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem. Biophys. Res. Commun. 355 (2007) 751-757
40. Vermeer A.W., Norde W., and van Amerongen A. The unfolding/denaturation of immunogammaglobulin of isotype 2b and its F(ab) and F(c) fragments. Biophys. J. 79 (2000) 2150-2154
41. Ionescu R.M., Vlasak J., Price C., and Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J. Pharm. Sci. 97 (2008) 1414-1426
42. Tischenko V.M., Zavyalov V.P., Medgyesi G.A., Potekhin S., and Privalov P.L. A thermodynamic study of cooperative structures in rabbit immunoglobulin G. Eur. J. Biochem. 126 (1982) 517-521
43. Roberge M., Estabrook M., Basler J., Chin R., Gualfetti P., Liu A., et al. Construction and optimization of a CC49-based scFv-β-lactamase fusion protein for ADEPT. Protein Eng. Des. Sel. 4 (2006) 141-145
44. Jung S., Honegger A., and Plückthun A. Selection for improved protein stability by phage display. J. Mol. Biol. 294 (1999) 163-180
45. Tischenko V.M., Abramov V.M., and Zavyalov V.P. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G. Biochemistry 37 (1998) 5576-5581
46. Batey S., and Clarke J. The folding pathway of a single domain in a multidomain protein is not affected by its neighbouring domain. J. Mol. Biol. 378 (2008) 297-301
47. Marvin J.S., and Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol. Sin. 6 (2005) 649-658
48. Lu D., Zhang H., Koo H., Tonra J., Balderes P., Prewett M., et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280 (2005) 19665-19772
49. Gavrilyuk J.I., Wuellner U., Salahuddin S., Goswami R.K., Sinha S.C., and Barbas III C.F. An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg. Med. Chem. Lett. 19 (2009) 3716-3720
50. Jendreyko N., Popkov M., Rader C., and Barbas III C.F. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc. Natl Acad. Sci. USA 102 (2005) 8293-8298
51. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning-A Laboratory Manual. 2nd ed. (1989), Cold Spring Habour Laboratory Press, New York
52. Privalov P.L., and Potekhin S.A. Scanning microcalorimetry in studying temperature-induced changes in proteins. Methods Enzymol. 131 (1986) 4-51
53. Myszka D.G. Improving biosensor analysis. J. Mol. Recognit. 12 (1999) 279-284